| Date/App# |
 List of recent Antibodies-related patents |
07/17/14
20140201856 |  Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. . |
07/17/14
20140201854 |  Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. . |
07/17/14
20140200180 |  Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins. |
07/17/14
20140200179 |  Wnt compositions and methods of use thereof
Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”. |
07/17/14
20140200165 |  Novel fab fragment libraries and methods for their use
The present invention provides fab libraries and methods for using the fab libraries to obtain antibodies against a target. The fab library of the invention contains at least 109 different fabs, and in some embodiments, at least 1010 different fabs. |
07/17/14
20140200160 |  Molecular-based method of cancer diagnosis and prognosis
A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. |
07/17/14
20140200156 |  Genes inducing agonistic effects by anti-c-met antibody treatment and drug screening method using the genes
Biomarkers for screening drugs reducing side effects of anti-c-met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-met antibodies.. . |
|
|
07/17/14
20140199763 |  Compositions and methods to immunize against hepatitis c virus
Compositions comprising viral antigens and antigenic peptides corresponding to or derived from hepatitis c virus (hcv) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (dcs) are described herein. Included herein are immunostimulatory compositions (hcv vaccines, hcv antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of hcv antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis c in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis c.. |
07/17/14
20140199729 |  Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. |
07/17/14
20140199361 |  Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
The invention relates to inhibitory anti-factor xii/fxiia antibodies and methods of their use.. . |
07/17/14
20140199328 | Interferon alpha antibodies and their uses
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. |
07/17/14
20140199323 | Monoclonal antibody
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. |
07/17/14
20140199321 | Stabilizing polypeptides which have been exposed to urea
Methods for stabilizing polypeptides, such as anti-her2 antibodies, which have been exposed to urea.. . |
07/17/14
20140199319 | Methods for increasing the efficiency of hybridoma generation
Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of igg expressing b cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas.. |
07/17/14
20140199318 | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably alzheimer's disease or vascular dementia.. . |
07/17/14
20140199317 | Actriia binding agents and uses thereof
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to actriia and uses for same.. . |
07/17/14
20140199315 | Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. |
07/17/14
20140199314 | Methods and compositions for regulating iron homeostasis by modulation of bmp-6
Modulation of iron homeostasis by regulating bmp-6 activity is provided. Methods of using bmp-6 and bmp-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. |
07/17/14
20140199313 | Process for the production of fine chemicals
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use.. |
07/17/14
20140199312 | Ddr1-binding agents and methods of use thereof
The present invention relates to ddr1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of ddr1 and modulate ddr1 activity. |
07/17/14
20140199310 | Compositions comprising agents that inhibit neuropilin and tolloid like 2
We disclose agents that inhibit the expression of neto-2 which has elevated expression in cancer stem cells; the use of neto-2 as a diagnostic or prognostic marker of tumour initiation; the use neto-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind neto-2 and vaccines comprising neto-2 polypeptides.. . |
07/17/14
20140199306 | Compositions and methods for antibodies targeting epo
The present invention relates to compositions and methods for the inhibition of epo. The invention provides antibodies and antigen binding fragments thereof that bind to epo and are able to inhibit epo-dependent cell proliferation and/or epo-dependent cell signaling.. |
07/17/14
20140199301 | Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr)
Phage displayed recombinant antibody library was developed and the library was screened against vegfr-2. After screening and elisa experiments two recombinant antibodies showing binding properties to vegfr-2 was obtained. |
07/17/14
20140199299 | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target cd3 on t cells and neutralize one or more biological activities of interleukin-6 (il-6), such as cd3 modulators including anti-cd3 antibodies and anti-il-6 antagonists including anti-il-6 antibodies, anti-il-6r antagonists including anti-il-6r antibodies, and/or anti-il-6/il-6r complex antagonists including anti-il-6/il-6r binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.. . |
07/17/14
20140199293 | Humanized antibody compositions and methods for binding lysophosphatidic acid
Compositions and methods for making and using humanized anti-lpa monoclonal antibodies, and fragments and derivatives thereof, are described.. . |
07/17/14
20140199268 | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. |
07/17/14
20140199242 | Compositions and methods for detection and treatment of cancer
Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the muc4 protein that does not comprise the central tandem repeat (tr) domain of muc4. |
07/17/14
20140199238 | Targeting of bone marrow neovasculature
Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (aml).. . |
07/17/14
20140199237 | Methods and compositions for modulation of olfml3 mediated angiogenesis
The present invention relates to antibodies against specific domains of olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the olfml3 antagonists.. |
07/10/14
20140196175 | Axmi221z, axmi222z, axmi223z, axmi224z and axmi225z delta-endotoxin genes and methods for their use
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. |
07/10/14
20140194600 | Use of anti-factor xi antibodies for prevention of thrombus formation
The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor xi and that inhibit factor xi activation and/or activity. The factor xi-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor xi activation and/or wherein inhibition of factor xi has a beneficial effect.. |
07/10/14
20140194599 | Anti-human interleukin-20 antibodies
Anti-human il20 monoclonal antibodies that can reduce il20 mediated activation of both il20r1/il20r2 and il22r1/il20r2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.. |
07/10/14
20140194598 | B7-related nucleic acids and polypeptides useful for immunomodulation
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3. |
07/10/14
20140194351 | Hemipteran-and coleopteran active toxin proteins from bacillus thuringiensis
A novel bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of lygus insects is significantly inhibited by providing the novel crystal protein in lygus insect diet. |
07/10/14
20140194306 | Nucleic acid sequences from diabrotica virgifera virgifera leconte and uses thereof
Expressed sequence tags (ests) isolated from the western corn rootworm, diabrotica virgifera virgifera leconte, are disclosed. The invention encompasses nucleic acid molecules that encode d. |
07/10/14
20140193899 | Monoclonal antibodies to fibroblast growth factor receptor 2
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. . |
07/10/14
20140193855 | Methods and compositions for determining the purity of chemically synthesized nucleic acids
This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.. |
07/10/14
20140193844 | Biomarkers for ankylosing spondylitis
There is described herein methods and peptides for detecting autoantibodies to nog and/or sost in a patient sample in order to diagnose of prognosticate ankylosing spondylitis in the patient.. . |
07/10/14
20140193838 | Method for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies
A method for measuring the amount of sialic acid in immunoglobulin g and immunoglobulin g anti-ds dna antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin g in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin g. |
07/10/14
20140193834 | Blood-brain barrier permeable peptide compositions
Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for alzheimer's disease. |
07/10/14
20140193829 | Monoclonal antibodies against scrapie prion protein
The present invention relates to monoclonal antibodies against prpsc protein. The anti-prpsc mabs produced of this invention can specifically detect prpsc protein from normal mouse brain homogenates without pre-treatment with protease k, which may be used in developing a diagnostic method and kit for prion disease with high specificity and sensitivity.. |
07/10/14
20140193467 | Compositions comprising tnf-specific antibodies for oral delivery
In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. |
07/10/14
20140193462 | Methods for cancer treatment using stem cells
Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells. |
07/10/14
20140193432 | Anti-hdlk-1 antibody having an antitumor activity in vivo
The present invention provides: antibodies specifically reacting against hdlk-1 and having anti-tumor activity in vivo (anti-hdlk-1 antibodies, and in particular, humanized anti-hdlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.. . |
07/10/14
20140193430 | Compositions and methods for regulating nk cell activity
The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of nk cells and allow a potentiation of nk cell cytotoxicity in mammalian subjects. |
07/10/14
20140193429 | Metal-citrate transporter antigen from streptomyces coelicolor and uses thereof
The present invention relates to an isolated antigen from streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. |
07/10/14
20140193428 | Human cytomegalovirus neutralizing antibodies and use thereof
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hcmv, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hcmv gene ul products. The invention also relates to immortalized b cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. |
07/10/14
20140193427 | Anti-gdf15 antibodies
Monoclonal antibodies that bind and inhibit the activity of human gdf15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human gdf15.. |
07/10/14
20140193426 | Markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chemotherapy
The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. |
07/10/14
20140193422 | Fully human antibodies against human 4-1bb
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1bb and that allow binding of human 4-1bb to a human 4-1bb ligand. In one aspect, the antibody is an igg4 antibody. |
07/10/14
20140193421 | Anti-human xcr1 antibodies
An object of the present invention is to provide a monoclonal antibody binding to human xcr1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of seq id no: 91.. . |
07/10/14
20140193418 | Anti-human epo receptor antibodies and methods of use
Herein is reported an antibody that specifically binds to human epo receptor, wherein the antibody binds to epo receptor fragment lpgpggsvdiv (seq id no: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kd.. . |
07/10/14
20140193417 | Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35. |
07/10/14
20140193415 | Bispecific anti-egfr/anti igf-1r antibodies
The present invention relates to bispecific anti-egfr/anti igf-1r antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. . |
07/10/14
20140193414 | Anti-her antibodies
The invention provides anti-her antibodies, including multispecific anti-her antibodies, compositions comprising and methods of using these antibodies. Also provided herein are egfr/her3 multispecific antibodies that are less toxic than traditional egfr antagonists.. |
07/10/14
20140193413 | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (vh) domain and/or a variable light chain (vl) domain, and wherein (a) the vh domain comprises complementarity determining regions (cdrs) selected from the group consisting of: a cdr1 sequence having identity to the sequence of seq id no: 7; a cdr2 sequence having identity to the sequence of seq id no: 8; and a cdr3 sequence having identity to the sequence of seq id no: 9 or 10; and/or (b) the vl domain comprises cdrs selected from the group consisting of: a cdr4 sequence having identity to the sequence of seq id no: 11; a cdr5 sequence having identity to the sequence of seq id no: 12; a cdr6 sequence having identity to the sequence of seq id no: 13.. . |
07/10/14
20140193405 | Humanized anti-cd40 antibodies
Provided are humanized anti-cd40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of cd40 antigen.. . |
07/10/14
20140193404 | Glycosylated antibodies
The invention provides an antibody comprising human igg1 or igg3 heavy chain constant domains that are glycosylated with a sugar chain at asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of ngna is 1% or less and/or the amount of n-terminal alpha 1,3 galactose is 1% or less, and uses thereof.. . |
07/10/14
20140193403 | Epitopes of il-17a and il-17f and antibodies specific thereto
The present invention relates neutralising epitopes of il-17a and il-17f and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.. |
07/10/14
20140193402 | Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity. |
07/10/14
20140193401 | Pertussis antibodies and uses thereof
Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.. |
07/10/14
20140193400 | Stable and soluble antibodies inhibiting tnf alpha
The present invention relates to particularly stable and soluble scfv antibodies and fab fragments specific for tnf, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of tnf, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of tnf-mediated disorders. |
07/10/14
20140193399 | Anti-cd3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen cd3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to cd3. |
07/10/14
20140193359 | Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2. |
07/10/14
20140193329 | Anti-cd151 antibodies and their use in the treatment of cancer
The present invention relates to new antibodies capable of binding specifically to the human cd151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the cd151 protein. |
07/03/14
20140187754 | Anti-fgfr3 antibodies and methods using same
The invention provides fgfr3 antibodies, and compositions comprising and methods of using these antibodies.. . |
07/03/14
20140187749 | Single unit chromatography antibody purification
The present invention relates to a method for the purification of antibodies from a protein mixture produced in a bioreactor, at least comprising the steps of intermediate purification and polishing, wherein the intermediate and polishing step comprises in-line anion exchange chromatography (aex) treatment and mixed mode chromatography (mimo) treatment in flow through mode. The present invention further relates to a single operational unit comprising both an anion exchange chromatography part and a mixed mode chromatography part, which are serially connected, wherein the unit comprises an inlet at the upstream end of the anion exchange chromatography part and an outlet at the downstream end of the mixed mode chromatography part and wherein the unit also comprises an inlet between the anion exchange chromatography part and the mixed mode chromatography part.. |
07/03/14
20140187485 | Novel receptor nucleic acids and polypeptides
Disclosed are nucleic acids encoding baff-r polypeptides, as well as antibodies to baff-r polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.. |
07/03/14
20140186973 | Assays for detecting neutralizing autoantibodies to biologic therapy
The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-tnfα drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. |
07/03/14
20140186972 | Apparatus and method for identifying a hook effect and expanding the dynamic range in point of care immunoassays
The present invention relates to systems and methods for the rapid in situ determination of the existence of a hook effect and expansion of the dynamic range of a point of care immunoassay. For example, a system for identifying a hook effect and expanding the dynamic range of an immunoassay is provided that may include a primary sensor having first immobilized antibodies that may be configured to generate a first signal based on a presence or absence of a target analyte in a sample. |
07/03/14
20140186933 | Method and device for detecting prior drug use, taking inflammation into account to increase test's specificity and reduce false positives
This method and device detects past use of drugs of abuse when the drug substance and its metabolites are no longer present in the body, based on the detection of the antibodies formed in response to said drug, and persist even after this drug and its metabolites are cleared from the body. False positive rate is reduced by screening out subjects with heightened inflammatory state. |
07/03/14
20140186892 | Monoclonal antibodies against glypican-3
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to glypican-3 with high affinity. Nucleic acid molecules encoding glypican-3 antibodies, expression vectors, host cells and methods for expressing the glypican-3 antibodies are also provided. |
07/03/14
20140186891 | Polynucleotides encoding il-31 monoclonal antibodies
The invention provides humanized mouse anti-human il-31 antibodies and antibody fragments that are capable of binding il-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of il-31.. . |
07/03/14
20140186889 | Antibody generation from plasmacytoma-prone transgenic animals
Certain transgenic animals which are prone to the rapid cell division of their antibody-secreting cells have superior properties for the generation of monoclonal antibodies. Not only can their antibody producing cells can be made into hybridomas with superior growth to hybridomas from non-prone animals, but the antibody producing cells themselves can be cultured directly without cell fusion or further manipulation. |
07/03/14
20140186861 | Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis
The present application provides methods of producing soluble treponema pallidum protein tp0453 (such as the fragment shown in seq id no: 3). For example, the protein can be expressed from the pet28a vector in a cell and the resulting soluble tp0453 protein isolated from the cell. |
07/03/14
20140186860 | Novel immunogenic proteins of leptospira
The invention provides novel immunogenic proteins liga and ligb from leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.. . |
07/03/14
20140186404 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. |
07/03/14
20140186383 | Novel simian t-cell lymphotropic virus
Disclosed are the simian t-cell lymphotropic virus type 3 subtype d (stlv-3 subtype d), isolated nucleic acid molecules encoding stlv-3 subtype d polypeptides, such as stlv-3 subtype d envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting stlv-3 subtype d, for example by detecting a stlv-3 subtype d nucleic acid or polypeptide in the sample. |
07/03/14
20140186380 | Immunotherapy with binding agents
Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. |
07/03/14
20140186377 | Prostaglandin e2 binding proteins and uses thereof
The present invention encompasses prostaglandin e2 (pge2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, cdr grafted and humanized. |
07/03/14
20140186374 | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory t cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory t cells in various disease settings is described. |
07/03/14
20140186373 | Antibody formulation
Anti-baffr antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. |
07/03/14
20140186371 | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
The invention provides antibodies that preferentially bind to ic3b relative to c3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment.. |
07/03/14
20140186370 | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus b5r envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus h3l envelope protein, and combinations thereof.. . |
07/03/14
20140186368 | Methods of administering anti-tnfalpha antibodies
Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate. |
07/03/14
20140186365 | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.. |
07/03/14
20140186363 | Magea3 binding antibodies
The present invention relates to magea3 binding antibodies.. . |
07/03/14
20140186362 | Anti-interferon gamma antibodies and methods of use thereof
The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hifnγ), thereby modulating the interaction between ifnγ and its receptor, ifnγ-r, and/or modulating the biological activities of ifnγ. The invention also relates to the use of such anti-ifnγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.. |
07/03/14
20140186360 | Phosphorylcholine conjugates and corresponding antibodies
In subjects with hypertension, increases in intima-media thickness (imt) at four years were less in subjects also having high autoantibodies particularly igm, to phosphorylcholine. The presence or absence of autoantibodies, particularly igm, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. |
07/03/14
20140186358 | Her3 antibodies binding to the beta-hairpin of her3
The invention relates to anti-her3 antigen binding proteins, e.g. Anti-her3 antibodies, that bind to the beta-hairpin of her3, methods for selecting these antigen binding proteins, their preparation and use as medicament.. |
07/03/14
20140186354 | Anti-her3/her4 antibodies binding to the beta-hairpin of her3 and the beta-hairpin of her4
The invention relates to anti-her3/her4 antigen binding proteins, e.g. Anti-her3/her4 antibodies, that bind to the beta-hairpin of her3 and the beta-hairpin of her4, methods for selecting these antigen binding proteins, their preparation and use as medicament.. |
07/03/14
20140186352 | Anti-granulysin antibodies and methods of use thereof
An anti-granulysin antibody, or an scfv or fab fragment thereof, capable of binding to an epitope region from r64 to r113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of seq id no:82 to seq id no:195, or the antibody may contain a sequence selected from the sequences of seq id no:39 to seq id no:76. |
07/03/14
20140186349 | Human cdr-grafted antibody and antibody fragment thereof
A human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human cc chemokine receptor 4 (ccr4) but does not react with a human blood platelet; a human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of ccr4 and has a cytotoxic activity against a ccr4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.. . |
07/03/14
20140186348 | Humanized and chimeric anti-properdin antibodies
An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3cdrs in seq id no: 1 and light chain variable domain including the 3cdrs in seq id no: 9.. . |
07/03/14
20140186346 | Methods of treating pain using an il-31ra or osmr-b antagonist
Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. |
07/03/14
20140186337 | Antitumors combinations containing antibodies recognizing specifically cd38 and bortezomib
Pharmaceutical composition comprising an antibody specifically recognizing cd38 and bortezomib.. . |
07/03/14
20140186334 | Surface, anchored fc-bait antibody display system
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell. |
07/03/14
20140186216 | Apparatus and method for identifying a hook effect and expanding the dynamic range in point of care immunoassays
The present invention relates to systems and methods for the rapid in situ determination of the existence of a hook effect and expansion of the dynamic range of a point of care immunoassay. For example, a system for identifying a hook effect and expanding the dynamic range of an immunoassay is provided that may include a primary sensor having first immobilized antibodies that may be configured to generate a first signal based on a presence or absence of a target analyte in a sample. |